Valganciclovir Tablets USP 450 mg

Therapeutic Class:

Dosage Forms:

Brand Name: Valgan 450

How it works?

Valganciclovir Tablets USP 450 mg – Valganciclovir is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).
Valganciclovir is indicated for the prevention of CMV disease in CMV-negative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a CMV-positive donor.

Valganciclovir is administered orally, and whenever possible, should be taken with food.
For paediatric patients who are unable to swallow valganciclovir film-coated tablets, valganciclovir powder for oral solution can be administered.

Skin and subcutaneous tissues disorders:
Common: Night sweats, Pruritus, Rash, Alopecia
Renal and urinary disorders:
Common: Renal impairment, Creatinine clearance renal decreased, Blood creatinine increased
Respiratory, thoracic and mediastinal disorders:
Very common: Cough, Dyspnoea
Gastrointestinal disorders:
Very common: Diarrhoea, Nausea, Vomiting, Abdominal pain
Common: Dyspepsia, Flatulence, Abdominal pain upper, Constipation
Very common: Neutropenia, Anaemia
Common: Thrombocytopenia, Leukopenia, Pancytopenia
Rare: Aplastic anaemia, Agranulocytosis, Granulocytopenia
Immune system disorders:
Common: Hypersensitivity
Psychiatric disorders:
Common: Depression, Confusional state, Anxiety
Uncommon: Agitation, Psychotic disorder, Thinking abnormal, Hallucinations
Nervous system disorders:
Common: Insomnia, Neuropathy peripheral, Dizziness, Paraesthesia, Hypoaesthesia
Eye disorders:
Common: Visual impairment, Retinal detachment, Vitreous floaters, Eye pain, Conjunctivitis

Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and penciclovir, a cross-hypersensitivity reaction between these drugs is possible.
Mutagenicity, teratogenicity, carcinogenicity, fertility, and contraception
Prior to the initiation of valganciclovir treatment, patients should be advised of the potential risks to the foetus. Valganciclovir should be considered a potential teratogen and carcinogen in humans with the potential to cause birth defects and cancers.
Valganciclovir has the potential to cause carcinogenicity and reproductive toxicity in the long term.
Severe leukopenia, neutropenia, anaemia, thrombocytopenia, pancytopenia, bone marrow failure and aplastic anaemia have been7 observed in patients treated with valganciclovir (and ganciclovir).
Valganciclovir should be used with caution in patients with pre-existing haematological cytopenia or a history of drug-related haematological cytopenia and in patients receiving radiotherapy.
Difference in bioavailability with oral ganciclovir
The bioavailability of ganciclovir after a single dose of 900 mg valganciclovir is approximately 60 %, compared with approximately 6 % after administration of 1000 mg oral ganciclovir (as capsules). When switching from induction to maintenance therapy and in patients who may switch from oral ganciclovir to valganciclovir as valganciclovir cannot be substituted for ganciclovir capsules on a one-to-one basis.
Renal impairment
In patients with impaired renal function, dosage adjustments based on creatinine clearance are required. Valganciclovir film-coated tablets should not be used in patients on haemodialysis.

Store below 30oC. Protect from light and moisture.
Keep the medicine out of reach of children.

10 × 1 × 10 Alu/Alu Blister.
Valgan 450 tablets are available in an Alu/Alu blister of 10 tablets. Such 01 blister in a monocarton and Such 10 monocartons in a unit carton with pack insert.

interested? let’s talk.

Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.

F. A. Q

Frequently Asked Questions

Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.

We have below MOQ for:

  1. Tablet, Capsules & Softgel: 200000 Units
  2. Ampoules : 100000 Units
  3. Vials: 10000 Units
  4. Ointment and Cream: 15000 Units
  5. Suppository: 50000 Units
  6. Syrup and Liquid: 10000 Units
  7. Sachets : 50000 Units

We do ready the product within 45-60 days after product artwork confirmation from your side. So, including transit time you can get the product within 90 days maximum, either by Air or Sea route.

A product's “shelf life” generally means the length of time you can expect a product to look and act as expected and to stay safe for use. This length of time varies, depending on the type of product, how it is used, and how it is stored.

Our products come with a minimum of 24 months to a maximum of 36 months of shelf life.

For, Primary packaging we use aluminium foil with 20 to 50 micron size and PVC foil with 350 to 400 micron depending on product characteristics and stability.

For, Secondary packing we do use 300 to 400 GSM FFB Card board.

For, Tertiary packing we do us 7 ply 150 GSM corrugated boxes to prevent the damage during transits.

Yes, we do have available for all dossier documents according to GMP guidelines for the respective country. We do also provide COPP and Free sale certificates (FSC) on demand to customers for special import permit type of commercial orders.